Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 220

1.

Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program.

Chen ZZ, Liu J, Morningstar J, Heckman-Stoddard BM, Lee CG, Dagogo-Jack S, Ferguson JF, Hamman RF, Knowler WC, Mather KJ, Perreault L, Florez JC, Wang TJ, Clish C, Temprosa M, Gerszten RE; and the Diabetes Prevention Program Research Group.

Diabetes. 2019 Oct 3. pii: db190236. doi: 10.2337/db19-0236. [Epub ahead of print]

PMID:
31582408
2.

Sickle Cell Trait, European Ancestry, and Longitudinal Tracking of HbA1c Among African Americans: The Jackson Heart Study.

Echouffo-Tcheugui JB, Mwasongwe SE, Sims M, Dagogo-Jack S, Golden SH, Correa A, Musani SK.

Diabetes Care. 2019 Oct;42(10):e166-e167. doi: 10.2337/dc19-0982. Epub 2019 Aug 20. No abstract available.

PMID:
31431453
3.

A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program.

Srinivasan S, Jablonski KA, Knowler WC, Dagogo-Jack S, E Kahn S, Boyko EJ, Bray GA, Horton ES, Hivert MF, Goldberg R, Chen L, Mercader J, Harden M, Florez JC; Diabetes Prevention Program Research Group.

J Endocr Soc. 2019 Jun 24;3(9):1663-1677. doi: 10.1210/js.2019-00069. eCollection 2019 Sep 1.

4.

Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664.

Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM; DCCT/EDIC Research Group.

Diabetes Care. 2019 Aug;42(8):e137. doi: 10.2337/dci19-0026. No abstract available.

PMID:
31332032
5.

Biomarkers of insulin action during single soccer sessions before and after a 12-week training period in type 2 diabetes patients on a caloric-restricted diet.

de Sousa MV, Fukui R, Dagogo-Jack S, Krustrup P, Zouhal H, da Silva MER.

Physiol Behav. 2019 Oct 1;209:112618. doi: 10.1016/j.physbeh.2019.112618. Epub 2019 Jul 16.

PMID:
31323295
6.

Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS).

Perreault L, Pan Q, Schroeder EB, Kalyani RR, Bray GA, Dagogo-Jack S, White NH, Goldberg RB, Kahn SE, Knowler WC, Mathioudakis N, Dabelea D; Diabetes Prevention Program Research Group.

Diabetes Care. 2019 Sep;42(9):1809-1815. doi: 10.2337/dc19-0244. Epub 2019 Jul 18.

PMID:
31320445
7.

Amino acid signature predictive of incident prediabetes: A case-control study nested within the longitudinal pathobiology of prediabetes in a biracial cohort.

Owei I, Umekwe N, Stentz F, Wan J, Dagogo-Jack S.

Metabolism. 2019 Sep;98:76-83. doi: 10.1016/j.metabol.2019.06.011. Epub 2019 Jun 19.

PMID:
31228482
8.

Prevention begets prevention - lessons from the Da Qing Study.

Dagogo-Jack S.

Nat Rev Endocrinol. 2019 Aug;15(8):442-443. doi: 10.1038/s41574-019-0227-1. No abstract available.

PMID:
31197267
9.

Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity.

Agbim U, Carr RM, Pickett-Blakely O, Dagogo-Jack S.

Curr Obes Rep. 2019 Sep;8(3):243-254. doi: 10.1007/s13679-019-00349-x. Review.

PMID:
31144261
10.

Predictive Value Positive of MTM Eligibility Criteria under MMA and ACA in Identifying Individuals with Medication Utilization Issues.

Qiao Y, Spivey CA, Wang J, Shih YT, Wan JY, Kuhle J, Dagogo-Jack S, Cushman WC, Chisholm-Burns M.

J Pharm Health Serv Res. 2018 Dec;9(4):393-401. doi: 10.1111/jphs.12266. Epub 2018 Sep 7.

PMID:
30906425
11.
12.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535. Erratum in: Endocr Pract. 2019 Feb;25(2):204.

PMID:
30742570
13.

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study.

Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM; DCCT/EDIC Research Group.

Diabetes Care. 2019 Apr;42(4):657-664. doi: 10.2337/dc18-1574. Epub 2019 Feb 6.

PMID:
30728218
14.

Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups.

Spivey CA, Qiao Y, Wang J, Shih YT, Wan JY, Dagogo-Jack S, Cushman WC, Hines LE, Chisholm-Burns MA.

J Am Geriatr Soc. 2019 Mar;67(3):581-587. doi: 10.1111/jgs.15754. Epub 2019 Jan 23.

PMID:
30674080
15.

Awareness of Prediabetes Status and Subsequent Health Behavior, Body Weight, and Blood Glucose Levels.

Owei I, Umekwe N, Ceesay F, Dagogo-Jack S.

J Am Board Fam Med. 2019 Jan-Feb;32(1):20-27. doi: 10.3122/jabfm.2019.01.180242.

16.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators.

N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.

PMID:
30415602
17.

Genetic Ancestry Markers and Difference in A1c Between African American and White in the Diabetes Prevention Program.

Hivert MF, Christophi CA, Jablonski KA, Edelstein SL, Kahn SE, Golden SH, Dagogo-Jack S, Mather KJ, Luchsinger JA, Caballero AE, Barrett-Connor E, Knowler WC, Florez JC, Herman WH.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):328-336. doi: 10.1210/jc.2018-01416.

PMID:
30358859
18.

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG; VERTIS-CV Investigators.

Am Heart J. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5.

19.

Physiology of Glycemic Recovery and Stabilization After Hyperinsulinemic Euglycemic Clamp in Healthy Subjects.

Owei I, Jain N, Jones D, Umekwe N, Dagogo-Jack S.

J Clin Endocrinol Metab. 2018 Nov 1;103(11):4155-4162. doi: 10.1210/jc.2018-01569.

PMID:
30239760
20.

Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study.

Qiao Y, Spivey CA, Wang J, Shih YT, Wan JY, Kuhle J, Dagogo-Jack S, Cushman WC, Chisholm-Burns MA.

Inquiry. 2018 Jan-Dec;55:46958018795749. doi: 10.1177/0046958018795749.

Supplemental Content

Loading ...
Support Center